Found: 27
Select item for more details and to access through your institution.
LKB1 and Tumor Metabolism: The Interplay of Immune and Angiogenic Microenvironment in Lung Cancer.
- Published in:
- International Journal of Molecular Sciences, 2019, v. 20, n. 8, p. 1874, doi. 10.3390/ijms20081874
- By:
- Publication type:
- Article
Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence.
- Published in:
- Current Oncology, 2022, v. 29, n. 1, p. 255, doi. 10.3390/curroncol29010024
- By:
- Publication type:
- Article
Co-Occurring Driver Genomic Alterations in Advanced Non-Small-Cell Lung Cancer (NSCLC): A Retrospective Analysis.
- Published in:
- Journal of Clinical Medicine, 2024, v. 13, n. 15, p. 4476, doi. 10.3390/jcm13154476
- By:
- Publication type:
- Article
Non-Small-Cell Lung Cancers (NSCLCs) Harboring RET Gene Fusion, from Their Discovery to the Advent of New Selective Potent RET Inhibitors: "Shadows and Fogs".
- Published in:
- Cancers, 2024, v. 16, n. 16, p. 2877, doi. 10.3390/cancers16162877
- By:
- Publication type:
- Article
Post-Progression Analysis of EGFR -Mutant NSCLC Following Osimertinib Therapy in Real-World Settings.
- Published in:
- Cancers, 2024, v. 16, n. 14, p. 2589, doi. 10.3390/cancers16142589
- By:
- Publication type:
- Article
Alectinib vs. Lorlatinib in the Front-Line Setting for ALK-Rearranged Non-Small-Cell Lung Cancer (NSCLC): A Deep Dive into the Main Differences across ALEX and CROWN Phase 3 Trials.
- Published in:
- Cancers, 2024, v. 16, n. 13, p. 2457, doi. 10.3390/cancers16132457
- By:
- Publication type:
- Article
Uncommon and Rare EGFR Mutations in Non-Small Cell Lung Cancer Patients with a Focus on Exon 20 Insertions and the Phase 3 PAPILLON Trial: The State of the Art.
- Published in:
- Cancers, 2024, v. 16, n. 7, p. 1331, doi. 10.3390/cancers16071331
- By:
- Publication type:
- Article
New Generations of Tyrosine Kinase Inhibitors in Treating NSCLC with Oncogene Addiction: Strengths and Limitations.
- Published in:
- Cancers, 2023, v. 15, n. 20, p. 5079, doi. 10.3390/cancers15205079
- By:
- Publication type:
- Article
MET in Non-Small-Cell Lung Cancer (NSCLC): Cross 'a Long and Winding Road' Looking for a Target.
- Published in:
- Cancers, 2023, v. 15, n. 19, p. 4779, doi. 10.3390/cancers15194779
- By:
- Publication type:
- Article
Association between Contrast-Enhanced Computed Tomography Radiomic Features, Genomic Alterations and Prognosis in Advanced Lung Adenocarcinoma Patients.
- Published in:
- Cancers, 2023, v. 15, n. 18, p. 4553, doi. 10.3390/cancers15184553
- By:
- Publication type:
- Article
Early Progression in Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Treated with Pembrolizumab in First-Line Setting: A Prognostic Scoring System Based on Clinical Features.
- Published in:
- Cancers, 2021, v. 13, n. 12, p. 2935, doi. 10.3390/cancers13122935
- By:
- Publication type:
- Article
Genomic Characterization of Concurrent Alterations in Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Mutations.
- Published in:
- Cancers, 2021, v. 13, n. 9, p. 2172, doi. 10.3390/cancers13092172
- By:
- Publication type:
- Article
Longitudinal liquid biopsy predicts clinical benefit from immunotherapy in advanced non-small cell lung cancer.
- Published in:
- NPJ Precision Oncology, 2024, v. 8, n. 1, p. 1, doi. 10.1038/s41698-024-00704-9
- By:
- Publication type:
- Article
STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer.
- Published in:
- Therapeutic Advances in Medical Oncology, 2018, v. 10, n. 1, p. 1, doi. 10.1177/1758835918763744
- By:
- Publication type:
- Article
Longitudinal liquid biopsy anticipates hyperprogression and early death in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Peripheral Blood Markers Identify Risk of Immune‐Related Toxicity in Advanced Non‐Small Cell Lung Cancer Treated with Immune‐Checkpoint Inhibitors.
- Published in:
- Oncologist, 2019, v. 24, n. 8, p. 1128, doi. 10.1634/theoncologist.2018-0563
- By:
- Publication type:
- Article
Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50%.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.980765
- By:
- Publication type:
- Article
Incorporating atezolizumab in the adjuvant setting of non-small cell lung cancer: key discussion points from an expert multidisciplinary panel by Italian Association of Thoracic Oncology.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.971042
- By:
- Publication type:
- Article
The Evolving Scenario of ES-SCLC Management: From Biology to New Cancer Therapeutics.
- Published in:
- Genes, 2024, v. 15, n. 6, p. 701, doi. 10.3390/genes15060701
- By:
- Publication type:
- Article
Overcoming resistance to osimertinib in non-small cell lung cancer: Hopes, doubts, and in-between.
- Published in:
- 2020
- By:
- Publication type:
- Editorial
Fears and Perception of the Impact of COVID-19 on Patients With Lung Cancer: A Mono-Institutional Survey.
- Published in:
- Frontiers in Oncology, 2020, v. 11, p. N.PAG, doi. 10.3389/fonc.2020.584612
- By:
- Publication type:
- Article
Results of Multilevel Containment Measures to Better Protect Lung Cancer Patients From COVID-19: The IEO Model.
- Published in:
- Frontiers in Oncology, 2020, v. 10, p. 1, doi. 10.3389/fonc.2020.00665
- By:
- Publication type:
- Article
Management of Non-Metastatic Non-Small Cell Lung Cancer (NSCLC) with Driver Gene Alterations: An Evolving Scenario.
- Published in:
- Current Oncology, 2024, v. 31, n. 9, p. 5121, doi. 10.3390/curroncol31090379
- By:
- Publication type:
- Article
Sharing Experience with Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors in Lung Cancer: An Italian Expert Panel Discussion.
- Published in:
- Current Oncology, 2023, v. 30, n. 11, p. 10033, doi. 10.3390/curroncol30110729
- By:
- Publication type:
- Article
Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?
- Published in:
- Current Oncology, 2023, v. 30, n. 5, p. 5072, doi. 10.3390/curroncol30050384
- By:
- Publication type:
- Article
Stage III Non-Small-Cell Lung Cancer: An Overview of Treatment Options.
- Published in:
- Current Oncology, 2023, v. 30, n. 3, p. 3160, doi. 10.3390/curroncol30030239
- By:
- Publication type:
- Article